Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

Table 3 Biochemical parameters of rats in different groups

Parameters	NC	HF	HF + SARO	HF + FENO	HF + PIO
ALT (IU/l)	33.47 ± 4.93	69.12 ± 7.33#	37.81 ± 4.51 ***	53.26 ± 8.61**	51.48 ± 9.71**
AST (IU/l)	42.29 ± 4.15	103.91 ± 16.75#	39.08 ± 12.56 ***	66.21 ± 5.01***	84.73 ± 5.37 *
Leptin (ng/ml)	1.41 ± 0.23	3.12 ± 0.65#	1.86 ± 0.53 ***	2.37 ± 0.41*	2.19 ± 0.31**
Adiponectin (mg/ml)	5.61 ± 0.78	1.55 ± 0.46#	4.70 ± 0.99 ***	3.95 ± 0.83 ***	3.39 ± 1.03 *

Values are expressed as the mean ± S.D. of 7 rats. Between group comparisons was tested by ANOVA followed by Tukey Kramer multiple comparisons test. NC normal control, HF high-fat emulsion, SARO Saroglitazar, FENO Fenofibrate, PIO Pioglitazone.^*p < 0.05; ^**p < 0.01; ^***p < 0.001; and ns (nonsignificant) vs. HF. ^# p < 0.001 vs. NC

ISSN: 2050-6511